Rockwell Medical’s (RMTI) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Rockwell Medical (NASDAQ:RMTI) in a research note released on Monday,Benzinga reports. HC Wainwright currently has a $2.50 price objective on the stock. HC Wainwright also issued estimates for Rockwell Medical’s Q4 2025 earnings at $0.04 EPS, FY2025 earnings at ($0.09) EPS, Q1 2026 earnings at ($0.01) EPS, Q2 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.01 EPS and FY2026 earnings at ($0.03) EPS.

Several other equities research analysts have also weighed in on RMTI. Wall Street Zen lowered Rockwell Medical from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rockwell Medical in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $2.50.

Rockwell Medical Trading Down 1.7%

Rockwell Medical stock opened at $1.13 on Monday. Rockwell Medical has a one year low of $0.78 and a one year high of $2.12. The company’s fifty day moving average price is $0.94 and its two-hundred day moving average price is $1.11. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.91 and a quick ratio of 3.50. The company has a market capitalization of $44.52 million, a price-to-earnings ratio of -7.06 and a beta of 1.65.

Hedge Funds Weigh In On Rockwell Medical

A number of institutional investors and hedge funds have recently bought and sold shares of RMTI. Vanguard Group Inc. raised its stake in Rockwell Medical by 12.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock valued at $1,625,000 after purchasing an additional 148,737 shares during the last quarter. GSA Capital Partners LLP grew its position in Rockwell Medical by 635.1% in the 3rd quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock worth $197,000 after purchasing an additional 141,672 shares during the last quarter. Finally, Panagora Asset Management Inc. bought a new position in shares of Rockwell Medical during the 2nd quarter worth about $41,000. Institutional investors own 23.31% of the company’s stock.

Key Stories Impacting Rockwell Medical

Here are the key news stories impacting Rockwell Medical this week:

• Positive Sentiment: Zacks upgraded RMTI to a Zacks Rank #2 (Buy), signaling improving earnings prospects that could attract buyers. Rockwell Medical (RMTI) Upgraded to Buy: Here’s What You Should Know
• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating, raised multiple quarterly and full‑year EPS estimates and maintains a $2.50 price target — analyst upgrades and tighter forecasts can support a higher share price if guidance/earnings follow. HC Wainwright Reaffirms “Buy” Rating for Rockwell Medical (NASDAQ:RMTI)
• Positive Sentiment: Zacks published pieces highlighting RMTI as undervalued and as a “fast‑paced momentum at a bargain” name — increased retail/institutional interest from such screens can boost demand. Is Rockwell Medical (RMTI) Stock Undervalued Right Now? Despite Fast-paced Momentum, Rockwell Medical (RMTI) Is Still a Bargain Stock
• Positive Sentiment: Short interest fell about 32% in January (to ~580.6k shares), reducing potential short‑term selling pressure and lowering a short‑squeeze risk profile — generally supportive for the share price.
• Neutral Sentiment: Company fundamentals/technicals: small market cap (~$45M), negative trailing P/E, elevated beta (1.65). The stock sits between its 50‑day (~$0.94) and 200‑day (~$1.11) moving averages, indicating mixed momentum with limited liquidity—this can amplify moves both ways.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.